An dieser Stelle informieren Sie über wissenschaftliche Veröffentlichungen, an denen wir mitgewirkt haben.
Virologie
- A novel method for recombinant mammalian-expressed S-HBsAg virus-like particle production for assembly status analysis and improved anti-HBs serology (Januar 2025 Link)
- Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants (30.07.2025 Link)
- Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells (Mai 2024 Link)
- Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests (12.03.2024 Link)
- Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023 (Januar 2024 Link)
- Zertifikat für die Unterstützung des Clinical Virology Network 2024 (Zertifikat)
- Limited antibody response after BA.4-5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: Results of a case series (Dezember 2023 Link)
- Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany (November 2023 Link)
- Convergent Klebsiella pneumoniae strains belonging to a sequence type 307 outbreak clone combine cefiderocol and carbapenem resistance with hypervirulence (31.10.2023 Link)
- In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2 (26.07.2023 Link)
- Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations (28.03.2023 Link)
- Magnipore: Prediction of differential single nucleotide changes in the Oxford Nanopore Technologies sequencing signal of SARS-CoV-2 samples(17.03.2023 Link)
- Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the Sotrovimab face but is escaped by Omicron (02.03.2023 Link)
- The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination (11.08.2022 Link)
- The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade (09.08.2022 Link)
- Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021 (25.06.2022 Link)
- Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection (02.06.2022 Link)
- Humoral immune response after different SARS-CoV-2 vaccination regimens (21.01.2022 Link)
- Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination (25.06.2021 Link)
- Estimating infectiousness throughout SARS-CoV-2 infection course (25.05.2021 Link)
- Fast Detection of SARS-CoV-2 RNA Directly from Respiratory Samples Using a Loop-Mediated Isothermal Amplification (LAMP) Test (29.04.2021 Link)
- Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study (07.04.2021 Link)
- Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen (28.12.2020 Link)
- Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests (12.11.2020 Link)
- Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection (13.10.2020 Link)
- Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera (15.06.2020 Link)
- Quadruplex real-time PCR for rapid detection of human alphaherpesviruses (24.01.2019 Link)